GlassScriptPhysician profile
Louisa Griggs
NPI 1659613065
$3,063.75
in general payments reported to CMS, 2019-2025
30 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $174 · 2021: $419 · 2022: $638 · 2023: $613 · 2024: $570 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.13 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.68 | 2019-2024 | |
| Astellas Pharma US INC | $335.58 | 2022-2025 | Veozah |
| Coopersurgical, INC. | $299.96 | 2020-2025 | Paragard T 380a, Wallach Cryosurgical Equipment, Fisherbrand Disposable Liquid Infant Heel Warmer |
| Sumitomo Pharma America, INC. | $250.56 | 2023-2024 | Myfembree |
| Organon LLC | $226.89 | 2021-2025 | Nexplanon, Nuvaring |
| Mayne Pharma Commercial LLC | $175.08 | 2022-2023 | |
| Myovant Sciences INC. | $115.38 | 2022 | |
| Merck Sharp & Dohme LLC | $109.00 | 2019-2024 | Gardasil, Gardasil 9 |
| Amgen INC. | $100.00 | 2021-2023 | Evenity, Prolia |
| Pfizer INC. | $90.21 | 2022-2024 | |
| Therapeuticsmd, INC. | $88.16 | 2019-2021 | |
| Roche Diagnostics Corporation | $87.11 | 2019 | |
| Avion Pharmaceuticals | $86.98 | 2021-2023 | Balcoltra |
| Exeltis, USA INC. | $79.00 | 2024-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $55.72 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $51.41 | 2019 | |
| Agile Therapeutics, INC. | $41.24 | 2024 | Twirla |
| Millicent US INC | $37.52 | 2024 | Femring, Intrarosa |
| Mission Pharmacal Company | $36.57 | 2023 | Citranatal |
| Scynexis, INC. | $36.26 | 2022 | |
| Boston Scientific Corporation | $31.43 | 2019 | |
| Lupin INC. | $30.25 | 2019-2020 | |
| Hologic Sales and Service, LLC | $22.16 | 2021 | |
| Vertical Pharmaceuticals, LLC | $20.87 | 2019 | |
| Ibsa Pharma INC. | $20.64 | 2023 | Tirosint, Licart |
| Minerva Surgical, INC | $16.42 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.07 | 2021 | |
| Allergan, INC. | $12.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louisa Griggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.